Alan Skarbnik, MD

An oncologist ruminates on emerging treatment options in follicular lymphoma and offers some clinical pearls.

Alan Skarbnik, MD, explains early relapse in follicular lymphoma and the available treatment options.

An expert describes typical monitoring strategies in follicular lymphoma.

Dr. Alan Skarbnik reviews the use of obinutuzumab-based therapies for follicular lymphoma and highlights data from a phase III study.

A key opinion leader discusses the considerations in choosing induction and maintenance therapy options for follicular lymphoma.

Alan Skarbnik, MD, presents the case of a 60-year-old man with newly diagnosed follicular lymphoma.

Alan Skarbnik, MD, director of the Chronic Lymphocytic Leukemia Program at John Theurer Cancer Center, discusses the possibility of triplet combinations for the treatment of hematologic malignances. The biggest challenge with this type of treatment regimen is the increased risk of adverse events.